Akston Biosciences Corporation (AXTN)
| Market Cap | 61.13M |
| Revenue (ttm) | 6.97M +222.3% |
| Net Income | 1.39M |
| EPS | 0.21 |
| Shares Out | 6.79M |
| PE Ratio | 43.82 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AXTN
Akston Biosciences is a pet biotechnology company focused on the development and commercialization of innovative biopharmaceutical products for cats, dogs, and other companion animals. Our current product portfolio includes multiple product candidates consisting of large molecule biologics that are designed to target significant opportunities in serious medical conditions in pets such as urothelial carcinoma (bladder cancer) in dogs, atopic dermatitis in dogs, chronic pain associated with arthritis in dogs, and obesity and metabolic disease in ... [Read more]
Financial Performance
Financial StatementsNews
Akston Biosciences IPO Registration Document (S-1)
Akston Biosciences has filed to go public with an IPO on the NYSE American.
Pet biotech Akston Biosciences files and sets terms for a $20 million IPO
Akston Biosciences, a biotech developing antibody and protein therapies for pets, filed on Wednesday with the SEC to raise up to $20 million in an initial public offering.